TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
BNR

Burning Rock Biotech Ltd

Healthcare · Diagnostics & Research · listed since 2020

18.60$ +3.3% vs. previous close Closing price · As of: Sep 25, 2026
🔔 Watch stock
Add to watchlist

Stock Watch

Stock Watch will tell you what changes at Burning Rock Biotech Ltd.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Price history

Chart

Interactive price chart (TradingView).

52-week range: 7.00 $ to 41.10 $ · Last price: 18.60 $ (As of: September 25, 2026)

Key figures

Key figures at a glance

Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.

Basics

Market Cap ?The value of the entire company on the market: share price times total shares outstanding. 0.2$B
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 9m
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 38.8%
Beta ?Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market. 1.4

Performance

Perf. 1M ?Price performance over the last month. -2.20%
Perf. 3M ?Price performance over the last 3 months. -35.70%
Perf. 6M ?Price performance over the last 6 months. -66.00%
YTD Performance (%) ?Price performance since the start of the year (Year to Date). -48.28%
52-Week-High Distance ?How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high. -74.6%
Perf. 1Y ?Price performance over the last 12 months. 97.59%
Perf. 3Y ?Price performance over the last 3 years. 81.82%
Perf. 5Y ?Price performance over the last 5 years. -90.39%
Perf. Since Inception ?Price performance since the first available trading day (06/12/2020) — with a complete history, that is since the IPO. -92.69%

Technical Indicators

MA 38 Days ?Moving average of the last 38 trading days: the smoothed price path. A price above it signals short-term strength. 11.00$
MA 50 Days ?Moving average of the last 50 trading days — the most widely watched medium-term trend line. 10.60$
MA 200 Days ?Moving average of the last 200 trading days — the dividing line between a long-term uptrend and downtrend. 17.20$
RSI (14) ?Relative Strength Index over 14 days, scale 0 to 100: above 70 counts as overbought, below 30 as oversold. A hint on timing, not a verdict on the company. 73.6
Volatility 30 Days ?Price swings over the last 30 trading days, annualized. The higher the value, the more the price fluctuates. 118.1%
Volatility 250 Days ?Price swings over the last 250 trading days (roughly one market year), annualized. 126.5%

Calculated from the price history · as of 09/25/2026

Valuation

P/E ?Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E. –
Forward P/E ?P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future. 0.0
PEG ?P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey. –
P/B ?Price-to-book ratio: market value relative to book equity. 2.7
P/S ?Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable. 2.6
EV/EBITDA ?Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero. -0.2
Price/FCF ?Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up. –

Profitability

Gross Margin ?Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power. 74.6%
EBIT Margin ?EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes. -17.5%
Net Margin ?Net margin: what's left of sales as profit after ALL costs, interest, and taxes. -13.6%
Return on Equity ?Return on equity: how much profit does the company generate per year on shareholders' equity? -10.9%
Return on Assets ?Return on assets: how much profit the company generates from its total assets (equity and debt combined). -5.2%

Balance Sheet & Safety

Equity Ratio ?Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet. 65.3%
Debt/Equity ?Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity. 0.03
Altman Z″ ?Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks. –
Piotroski ?Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag. 6 out of 9

Growth

Sales Growth Last Quarter ?Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY). -18.90%
EPS Growth Last Quarter ?Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY). 0.00%
Sales Growth (Year) ?Sales growth in the last fiscal year versus the year before. 4.60%
Forward Sales Growth ?Sales growth analysts expect over the next 12 months — an estimate, not a guarantee. –
Forward EPS Growth ?Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee. –

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage ?Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line. –
RS Rating ?Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks. –
EPS Rating ?Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth. –
Fundamental Rating ?Our own Fundamental Rating: 0 to 100 points with an A+ to F grade. 50 points is the average across the universe, 100 the best possible score. It scores growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety — every stock percentile-ranked against all others. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below. D (37 out of 100)

Comparison

Industry comparison

The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.

Industry: Diagnostics & Research

Industry comparison
Company Market cap ($B) P/E EV/EBITDA Gross Margin % EBIT Margin % Sales Growth (Year) % Perf. 1Y %
Burning Rock Biotech Ltd BNR 0.2 – -0.2 74.6 -17.5 4.6 97.6
Thermo Fisher Scientific Inc TMO 248.0 37.8 23.4 41.0 17.9 3.9 47.5
Danaher Corporation DHR 158.5 44.2 23.4 58.8 22.9 2.9 24.6
Natera Inc NTRA 59.4 – -26.8 65.2 -12.4 35.9 149.4
Agilent Technologies Inc A 48.9 34.3 24.0 53.7 23.7 6.7 40.1
IQVIA Holdings Inc IQV 45.3 34.0 16.5 33.0 13.6 5.9 51.7
Waters Corporation WAT 42.6 53.9 47.8 56.3 2.8 7.0 47.0
IDEXX Laboratories Inc IDXX 41.3 38.6 26.0 62.5 31.8 10.4 -18.1
Illumina Inc ILMN 40.8 48.1 28.0 67.9 18.3 -0.8 192.9
Median of companies shown 45.3 38.6 23.4 58.8 17.9 5.9 47.5

Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →

Fiscal years

Annual Figures

Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.

Revenue, operating income and net income per fiscal year CNY m

Revenue Operating income Net income

2017 · Revenue: 111 CNY m 2017 · Operating income: -121 CNY m 2017 · Net income: -131 CNY m 2018 · Revenue: 209 CNY m 2018 · Operating income: -161 CNY m 2018 · Net income: -178 CNY m 2019 · Revenue: 382 CNY m 2019 · Operating income: -169 CNY m 2019 · Net income: -168 CNY m 2020 · Revenue: 430 CNY m 2020 · Operating income: -412 CNY m 2020 · Net income: -407 CNY m 2021 · Revenue: 508 CNY m 2021 · Operating income: -797 CNY m 2021 · Net income: -797 CNY m 2022 · Revenue: 563 CNY m 2022 · Operating income: -980 CNY m 2022 · Net income: -971 CNY m 2023 · Revenue: 537 CNY m 2023 · Operating income: -669 CNY m 2023 · Net income: -654 CNY m 2024 · Revenue: 516 CNY m 2024 · Operating income: -358 CNY m 2024 · Net income: -347 CNY m 2025 · Revenue: 540 CNY m 2025 · Operating income: -55 CNY m 2025 · Net income: -55 CNY m
201720182019202020212022202320242025
Annual Figures
Fiscal Year Revenue (CNY m) EBIT (CNY m) Net Income (CNY m) EPS (CNY) Operating Cash Flow (CNY m) Equity (CNY m) Total Assets (CNY m)
2017 111 -121 -131 -72.57 -134 168 400
2018 209 -161 -178 -79.31 -149 -603 373
2019 382 -169 -168 -71.68 -228 -891 848
2020 430 -412 -407 -59.33 -74 2,421 2,663
2021 508 -797 -797 -76.45 -478 1,845 2,279
2022 563 -980 -971 -93.47 -457 1,158 1,587
2023 537 -669 -654 -63.84 -256 768 1,040
2024 516 -358 -347 -33.67 -92 581 885
2025 540 -55 -55 -51.32 -28 536 821

Quarters

Quarterly Figures

Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter (CNY m)
2024: Q2 · 135.5 CNY m Q2 2024: Q3 · 128.6 CNY m Q3 2024: Q4 · 126.0 CNY m Q4 2025: Q1 · 133.1 CNY m Q1 2025: Q2 · 148.6 CNY m Q2 2025: Q3 · 131.6 CNY m Q3 2025: Q4 · 124.6 CNY m Q4 2026: Q1 · 107.9 CNY m Q1

Source: fundamental data

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales (CNY m) Sales YoY (%) Net Margin (%) OCF (CNY m) FCF (CNY m)
2024: Q2 -1.45 -13.60 136 -7.30 -79.70 -41 -41
2024: Q3 -0.48 71.70 129 0.80 -27.80 -30 -30
2024: Q4 -7.87 -156.40 126 4.10 -64.50 19 19
2025: Q1 -1.25 24.20 133 5.90 -10.10 -24 -29
2025: Q2 -0.90 38.10 149 9.60 -6.50 -44 -44
2025: Q3 -1.56 -222.90 132 2.30 -12.70 16 16
2025: Q4 – – 125 -1.20 -12.20 23 23
2026: Q1 -0.21 83.50 108 -18.90 -16.20 -29 -35

What Do These Terms Mean?

EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

Compare with other stocks →

Screening

Appears in These Scanners

This stock currently matches 1 of our scanner strategies — each hit links to the scanner.

Growth

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners

Outlook

Analysts & Price Target

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Consensus Strong Sell 1 = Strong buy … 5 = Strong sell
Analyst Ratings 1
Price Target (average) 4.03$
Distance to price -78.3% The price target sits 78.3% below the current price.

Distribution of Recommendations

Strong Buy 1
Buy 0
Hold 0
Sell 0
Strong Sell 0

AI classification

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.

How the Rating Is Built

Growth

Growth Score

Ten checks against the annual reports — each one passed counts a point.

4 of 10 Weak growth
  • Revenue grows by more than 15% a year over three years -1.4%
  • More than 10% revenue growth is expected for the coming year no data
  • Share count grows by less than 3% a year -53.0%
  • Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -1.6%
  • Gross margin at 40% or higher and without meaningful erosion 74.7%
  • Goodwill from acquisitions does not grow faster than revenue 0.0%
  • Net debt below twice EBITDA 438 m net cash
  • Operating cash flow covers the profits of the last three years 679 m
  • Return on capital at 15% or higher, or up versus two years ago -9.6%
  • Insiders hold at least 10% or are net buyers 4.0%

A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail

Quality check

AAQS

2/10

The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).

  • Sales growth 10Y > 5% 21.8%
  • Exp. sales growth 3Y > 5% –
  • EBIT growth 10Y > 5% –
  • Exp. EBIT growth 3Y > 5% –
  • Net debt < 4x EBIT –
  • EBIT positive, 10Y straight 0
  • Max. EBIT decline < 50% –
  • Return on equity > 15% -10.3%
  • ROCE > 15% -9.6%
  • Expected return > 10% –

View stocks with the full AAQS score · Read the methodology at AlleAktien

Source: fundamental data

The company

About the Company

Burning Rock Biotech Limited entwickelt und verkauft Tests zur Auswahl von Krebstherapien in der Volksrepublik China und den Vereinigten Staaten. Das Unternehmen ist in drei Segmenten tätig: Zentrallabor-Geschäft, Krankenhaus-internes Geschäft sowie Pharma-Forschungs- und Entwicklungsdienstleistungen. Das Unternehmen bietet auf Next-Generation-Sequencing (NGS) basierende Gewebe- und Flüssigbiopsietests zur Auswahl von Krebstherapien sowie Prognosetests für verschiedene Krebsarten an, darunter Lungenkrebs, Magen-Darm-Krebs, Prostatakrebs, Brustkrebs, Lymphome, Schilddrüsenkrebs, Darmkrebs, Eierstockkrebs, Bauchspeicheldrüsenkrebs und Blasenkrebs unter Verwendung von Gewebe- und Flüssigbiopsieproben. Zu den Hauptprodukten zählen OncoScreen Focus, ein Multi-Gen-Tumormutations-Ko-Nachweiskit für Patienten mit nicht-kleinzelligem Lungenkrebs (NSCLC); OncoScreen Plus, ein pankrebs-übergreifender Test für Gewebeproben; OncoCompass Plus, der entsprechende Test für Flüssigbiopsieproben; OncoCompass Target, ein auf ctDNA-Flüssigbiopsie basierender Test für NSCLC; sowie ColonCore zur Bewertung von Mikrosatelliten-Loci im Zusammenhang mit MSI-Status und zum Nachweis von Mutationen in Genen, die mit Magen-Darm- und verwandten Krebsarten in Zusammenhang stehen. Das Unternehmen bietet außerdem CanCatch, einen präoperativen ctDNA-Nachweis und postoperative Erkennung minimaler Resterkrankung bei Patienten mit Rückfall; OncoMaster, eine automatische Maschine zur NGS-Datenanalyse und Berichtsinterpretation; sowie Magnis, eine BR-angepasste Version seiner Hauptprodukte. Darüber hinaus ist es an der Vermittlung des Verkaufs von Laborgeräten sowie am Verkauf von Reagenzienkits beteiligt. Das Unternehmen hat eine Entwicklungs- und Vermarktungsvereinbarung mit Myriad Genetics, Inc. zur Einlizenzierung des Myriad-myChoice-Tumortests in China sowie Kooperationen bei klinischen Studien und Forschungsstudien mit AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim und Merck KGaA. Burning Rock Biotech Limited wurde 2014 gegründet und hat seinen Hauptsitz in Guangzhou, Volksrepublik China.

Employees
667
Headquarters
Guangzhou, China
Address
No. 5, Xingdao Ring Road North, 510005 Guangzhou, China
Phone
86 20 3403 7871
IPO Date
06/12/2020
ISIN
US12233L2060
Stock Split
1:10 on 05/15/2024

Management

Management
Name Title Birth Year
Yusheng Han Founder, Chairman & CEO 1979
Xiaozhi Hu Vice President of Finance 1984
Zhihong Zhang CTO & Director 1976
Hao Liu Senior Advisor 1974
Xinru Mao Senior VP of Pharma Biomarker & CDx. Services and International Diagnostics Division –

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?